Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Africa ETF (EZA) vs Viatris Inc (VTRS) Price & Performance

iShares MSCI South Africa ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI South Africa ETF vs Viatris Inc — how do they compare? iShares MSCI South Africa ETF trades at $63.5 (market cap $455.34M), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 44× iShares MSCI South Africa ETF's market cap, and Viatris Inc pays a 2.75% dividend while iShares MSCI South Africa ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and Viatris Inc for 57 Days on average.

EZAVTRS
Market Cap
$455.34M$20.03B
Volume
148,69214,109,977
Sector
Broad Market / FactorHealth
52-Week High
$81.60$18.27
52-Week Low
$60.43$9.74
Typical Hold Time
70 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Africa ETF

EZA trades at $62.29, down 2.15% today, with a bearish technical signal driven by moving averages. The ETF's portfolio faces headwinds from global reflation impacting its heavy exposure to South African gold, banking, and platinum group metals. Key oscillators like the 6-day and 12-day relative strength index indicate oversold conditions, suggesting potential for a near-term bounce, but the average directional index signals a strong downtrend.

The outlook is cautious due to macroeconomic pressures on constituent companies, with risks from higher capital costs and commodity price volatility. Investment opportunity hinges on a reversal in global yield curves and commodity markets, but current sentiment remains negative amid sell-side dominance and lack of positive fundamental catalysts.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.

Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EZA
100% Buy0% Sell
Avg holding period · 70 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares MSCI South Africa ETF

EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.

Read more on EZA →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →